Provided by Tiger Trade Technology Pte. Ltd.

Vera Therapeutics, Inc.

33.67
-0.3800-1.12%
Post-market: 33.50-0.1700-0.50%19:59 EDT
Volume:10.49M
Turnover:364.28M
Market Cap:2.41B
PE:-5.71
High:37.14
Open:37.14
Low:32.73
Close:34.05
52wk High:56.05
52wk Low:23.05
Shares:71.71M
Float Shares:52.39M
Volume Ratio:5.29
T/O Rate:20.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8984
EPS(LYR):-4.6644
ROE:-91.75%
ROA:-46.76%
PB:5.92
PE(LYR):-7.22

Loading ...

U.S. Stocks on the MOVE-Forgent Power, Vera Bradley, Wells Fargo

Reuters
·
12 hours ago

Top Midday Stories: Waystar Reportedly Mulling Potential Sale; Intel-Backed Altera Says Parent Company Files Confidentially for IPO

MT Newswires Live
·
Yesterday

Rami Katkhuda Reiterates Buy on Trutakna, Citing Strong Clinical and Early Commercial Traction; $90 Price Target Maintained

TIPRANKS
·
Yesterday

Vera Therapeutics ORIGIN 3 study results positive, says Raymond James

TIPRANKS
·
Yesterday

Vera Therapeutics Shares up 1.5% After Kidney Disease Drug Meets Goals in Confirmatory Trial

THOMSON REUTERS
·
Yesterday

U.S. Stocks on the MOVE-Eli Lilly, Waystar, Sysco

Reuters
·
Yesterday

Vera Therapeutics Shares Gain on Positive Late-Stage Trial Results

Dow Jones
·
Yesterday

Vera Therapeutics Reports Successful TRUTAKNA Phase 3 Results

TIPRANKS
·
Yesterday

Top Premarket Gainers

MT Newswires Live
·
Yesterday

Vera Therapeutics up 13% in pre-market at $38.63 after trutakna ORIGIN 3 data

TIPRANKS
·
Yesterday

Vera Therapeutics Gains After Kidney Disease Drug Meets Goals in Confirmatory Trial

Reuters
·
Yesterday

Vera Therapeutics’ trutakna meets all efficacy endpoints in IgAN trial

TIPRANKS
·
Yesterday

Vera Therapeutics, - Trutakna Demonstrates Favorable Safety Profile Generally Comparable to Placebo

THOMSON REUTERS
·
Yesterday

Vera Therapeutics, - Plans to Submit Supplemental Bla to FDA for Full Approval in Q4 2026

THOMSON REUTERS
·
Yesterday

Vera Therapeutics Announces Trutakna™ (Atacicept-Vymj) Stabilized Egfr and Prevented Kidney Disease Progression Through Two Years in Origin 3 Final Efficacy Analysis in Iga Nephropathy

THOMSON REUTERS
·
Yesterday

Vera Therapeutics, - Trutakna Meets All Prespecified Endpoints in Origin 3 Final Efficacy Analysis

THOMSON REUTERS
·
Yesterday

Vera Therapeutics is Maintained at Overweight by JP Morgan

Dow Jones
·
Sep 08

U.S. Research Roundup-Fedex Freight Holding Company, PDF Solutions, Robinhood Markets

Reuters
·
Sep 08

Vera Therapeutics, Inc. : JP Morgan Raises Target Price to $83 from $76

THOMSON REUTERS
·
Sep 08

Vera Therapeutics CEO Fordyce Marshall Disposes of USD 649,642 Common Shares

Reuters
·
Sep 05